Every Form 4 that Cellectar Biosciences INC NEW (CLRB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLRB filings page.
Cellectar Biosciences, Inc. reported that consultant Loren Stefan received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.6900 per share and expire on July 8, 2036. The award vests in full on July 8, 2027, subject to continued service through that date. Following this grant, Stefan holds 15,000 stock options directly.
Kolean Chad J reported acquisition or exercise transactions in this Form 4 filing.
Cellectar Biosciences CFO Chad J. Kolean received a grant of 92,000 stock options to buy common shares at $3.14 per share. The options were contingently granted on May 28, 2026, under Cellectar's amended 2021 Stock Incentive Plan and became effective after stockholders approved the plan on July 7, 2026.
The award vests over three years from May 28, 2026, with one-third vesting on the first anniversary and the remaining two-thirds vesting in 24 equal monthly installments thereafter. Following this grant, Kolean holds 92,000 stock options directly under this award.
Cellectar Biosciences director Frederick W. Driscoll received a grant of stock options representing 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. They vest in full on July 7, 2027, subject to his continued service, and this grant brings his reported option holdings from this award to 25,000 derivative securities.
Cellectar Biosciences director Asher Chanan-Khan received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. According to the terms, the entire grant will vest on July 7, 2027, provided he continues to serve through that date. Following this grant, his reported holdings include 25,000 stock options directly.
Cellectar Biosciences President & CEO James V. Caruso received a grant of stock options to acquire 250,000 shares of common stock at an exercise price of $3.14 per share. These options were contingently granted on May 28, 2026, subject to stockholder approval of the amended 2021 Stock Incentive Plan.
Stockholders approved the amended plan at Cellectar’s 2026 Annual Meeting of Stockholders on July 7, 2026, activating the grant. The options expire on May 28, 2036 and vest over three years, with one-third vesting on May 28, 2027 and the remainder vesting in 24 equal monthly installments thereafter.
Cellectar Biosciences director Andrew Gu received a grant of stock options as equity compensation. On July 7, 2026, he was awarded options covering 25,000 shares of common stock with an exercise price of $2.70 per share and an expiration date of July 7, 2036. According to the footnote, the option vests in full on July 7, 2027, provided he continues to serve the company through that date.
Cellectar Biosciences Chief Operating Officer Jarrod Longcor received a grant of stock options as equity compensation. The award covers 118,000 shares of common stock at an exercise price of $3.14 per share and expires on May 28, 2036.
The option was contingently granted on May 28, 2026 and became effective after stockholders approved the amended 2021 Stock Incentive Plan on July 7, 2026. It vests over three years, with one-third vesting on the first anniversary of May 28, 2026 and the remaining two-thirds vesting in 24 equal monthly installments thereafter.
Cellectar Biosciences director Douglas J. Swirsky received a grant of stock options covering 37,500 shares of common stock at an exercise price of $2.70 per share. The option vests in full on July 7, 2027, subject to his continued service, and expires on July 7, 2036. This is a compensation grant, with no open-market share purchases or sales reported.
Cellectar Biosciences director John Neis received a grant of stock options covering 25,000 shares of common stock. The options were awarded at an exercise price of $2.70 per share and expire on July 7, 2036. Following this grant, he holds options for 25,000 shares.
According to the footnote, the option vests in full on July 7, 2027, subject to his continued service through that vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Cellectar Biosciences, Inc. reported that consultant Loren Stefan received a grant of stock options. The award covers 15,000 stock options with an exercise price of $2.6800 per share, expiring on July 8, 2036. These options relate to 15,000 shares of common stock and will vest in full on July 8, 2027, subject to continued service. Following this grant, Stefan holds 15,000 derivative securities directly.
Cellectar Biosciences, Inc. Chief Operating Officer Jarrod Longcor reported open-market purchases of common stock and warrants. On 2026-05-07, he bought 8,680 shares of common stock at $2.88 per share. He also bought 26,040 warrants at $0.01 per warrant, each exercisable for one share of common stock at an exercise price of $2.88.
After these transactions, his direct holdings increased to 20,451 common shares and 36,149 warrants. A footnote explains the warrants are split into Tranche A, Tranche B, and Tranche C, with terms of one, two, and five years, respectively, from the date of stockholder approval.
Cellectar Biosciences, Inc. director and Chief Executive Officer James V Caruso reported buying common stock and warrants in an open-market transaction. He purchased 8,680 shares of common stock at $2.88 per share and 26,040 warrants at $0.01 per warrant, each relating to common stock at a $2.88 exercise price. Following these transactions, he directly holds 20,318 shares of common stock and 36,076 warrants. A footnote explains that the warrants are divided into tranches with terms of one, two, and five years from the date of stockholder approval.
Cellectar Biosciences director John Neis reported selling 198 shares of the company’s common stock on December 12, 2025 at a weighted average price of $3.6969 per share. The shares were sold in multiple trades at prices ranging from $3.631 to $3.70.
Following this transaction, he is reported as beneficially owning 10 shares of common stock indirectly, held through Advantage Capital Wisconsin Partners I, Limited Partnership. The reported share amount reflects adjustments for prior reverse stock splits in 2018, 2022, and 2025.